Business Context and Reporting Period
Company: Qualigen Therapeutics, Inc. (Ticker: QLGN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Qualigen is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Its portfolio includes one early-clinical-stage program (QN-302 for pancreatic cancer) and one preclinical program (Pan-RAS). The company also holds a co-development agreement with Marizyme, Inc. regarding a vascular conduit solution. The company operates as a "virtual" entity with no employees as of June 2025.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 (Continuing Operations) |
| Net Loss (Continuing Ops) | $(6.16) million | $(12.48) million |
| Total Net Loss | $(6.26) million | $(13.76) million |
| Cash and Cash Equivalents | $1.17 million | $0.40 million |
| Accumulated Deficit | $(123.1) million | $(116.8) million |
| Operating Cash Flow | $(6.33) million | $(10.30) million |
| Financing Cash Flow | $9.01 million | $(0.55) million |
| Current Liabilities | $2.01 million | $4.14 million |
Note: The company reported no revenue from continuing operations. Discontinued operations (Qualigen Inc. and NanoSynex) generated revenue in 2023 but were divested or deconsolidated.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 49% from $11.3 million in 2023 to $5.8 million in 2024. This was driven by significant reductions in Research and Development (R&D) costs (down $4.0 million) and General and Administrative (G&A) expenses (down $1.9 million) due to workforce reductions and slowed development activities.
- Capital Raises: In 2024, the company raised approximately $8.0 million in equity (Series A-2 Preferred Stock and common stock) and $3.5 million in debt, compared to no new equity or debt issuance in 2023.
- Stock Split: A 1-for-50 reverse stock split was effected on November 5, 2024, to regain compliance with Nasdaq listing requirements. All share data is presented on a post-split basis.
- Discontinued Operations: The company recorded a $0.1 million loss on the disposal of discontinued operations in 2024 (early settlement of escrow from the 2023 sale of Qualigen Inc.), compared to a $1.3 million loss in 2023.
Guidance, Outlook, and Risks
- Going Concern: The company has an accumulated deficit of $123.1 million and recurring losses. Management expects cash balances to fund operations only into the third quarter of 2025. The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Development Status: Due to financial constraints, the company slowed the development of its therapeutic products (QN-302 and Pan-RAS) beginning in the second quarter of 2024. Development will ramp up only when properly funded.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to a lack of accounting personnel, inadequate segregation of duties, and insufficient IT general controls. This contributed to a late filing of the 2024 Annual Report.
- Legal Proceedings: The company is defending against a lawsuit filed by LifeSci Capital LLC alleging breach of contract and seeking damages of approximately $503,000. The company disputes the claim.
- Delisting Risk: The company received notice from Nasdaq regarding delisting due to late filing of the 2024 Form 10-K. An appeal was filed, but there is no assurance of regaining compliance.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure additional financing before the projected third quarter of 2025 cash exhaustion.
- Internal Control Remediation: Assess the timeline and funding required to remediate the material weakness in internal controls over financial reporting.
- Nasdaq Compliance: Monitor the status of the Nasdaq delisting appeal and the company's ability to maintain listing standards.
- Marizyme Exposure: Review the credit risk associated with the $2.36 million in notes receivable from Marizyme, Inc., for which a $360,000 allowance for credit losses has been recorded.
- Legal Liability: Track the outcome of the LifeSci Capital LLC litigation and potential financial impact.